- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.01. | SAB Biotherapeutics, Inc.: SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director | 2 | GlobeNewswire (USA) | ||
| 07.01. | SAB Biotherapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 29.12.25 | SAB Biotherapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 19.12.25 | Guggenheim initiates SAB Biotherapeutics stock with Buy rating on T1D potential | 5 | Investing.com | ||
| 18.12.25 | SAB Biotherapeutics, Inc.: First Patient Dosed in SAB BIO's SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D | 244 | GlobeNewswire (Europe) | Enrollment in the SAFEGUARD trial is ongoing at multiple centers globallyCompany on-track to share Phase 2b data in 2H 2027 MIAMI, Dec. 18, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq:... ► Artikel lesen | |
| 17.12.25 | SAB Biotherapeutics, Inc.: SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D | 192 | GlobeNewswire (Europe) | Phase 1 data confirms SAB-142 does not cause serum sickness and has low/no immunogenicity at any dose and in all cohorts, including redosed healthy volunteersStudy results support the chronic dosing... ► Artikel lesen | |
| 15.12.25 | SAB Biotherapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 13.11.25 | SAB BioTherapeutics reports Q3 results | 1 | Seeking Alpha | ||
| SAB BIOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 13.11.25 | SAB Biotherapeutics, Inc.: SAB BIO Reports Third Quarter Financial Results and Recent Business Highlights | 121 | GlobeNewswire (Europe) | Initiated registrational Phase 2b SAFEGUARD trial of SAB-142 in new-onset, Stage 3 autoimmune T1D patientsMultiple SAFEGUARD trial sites activated; on-track to dose first patient by year-endRecent... ► Artikel lesen | |
| 30.09.25 | SAB Biotherapeutics verkleinert Verwaltungsrat nach Rücktritt von zwei Direktoren | 9 | Investing.com Deutsch | ||
| 26.09.25 | SAB Biotherapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 22.09.25 | SAB Biotherapeutics stock maintains Buy rating at H.C. Wainwright on positive diabetes treatment data | 2 | Investing.com | ||
| 19.09.25 | SAB Biotherapeutics, Inc.: SAB BIO Highlights Data in Multiple Presentations at EASD | 1 | GlobeNewswire (USA) | ||
| 03.09.25 | SAB Biotherapeutics, Inc.: SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes | 2 | GlobeNewswire (USA) | ||
| 02.09.25 | SAB BioTherapeutics files to sell 250M shares of common stock for holders | 1 | Seeking Alpha | ||
| 08.08.25 | Chardan Capital senkt Kursziel für SAB Biotherapeutics auf 12 US-Dollar | 2 | Investing.com Deutsch | ||
| 07.08.25 | SAB Biotherapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 09.05.25 | SAB Biotherapeutics, Inc.: SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates | 542 | GlobeNewswire (Europe) | MIAMI, May 09, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), ("SAB BIO" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human... ► Artikel lesen | |
| 31.03.25 | SAB Biotherapeutics, Inc.: SAB BIO Reports Full Year 2024 Operating and Financial Results | 563 | GlobeNewswire (Europe) | MIAMI, March 31, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), ("SAB BIO" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 95,80 | -0,21 % | BASF unter DRUCK! KAUFEMPFEHLUNGEN für BioNTech und WashTec Aktie! | Marktführerschaft, Effizienzsteigerung, Dividende und Aktienrückkauf - alles gute Gründe, um die Aktie von WashTec zu kaufen. Diese Einschätzung teilen auch die Analysten von MM Warburg. Ihre Gewinnschätzungen... ► Artikel lesen | |
| AMGEN | 288,20 | -0,10 % | Amgen, Kyowa Kirin End Collaboration On Atopic Dermatitis Drug Rocatinlimab | THOUSAND OAKS (dpa-AFX) - Kyowa Kirin Co., Ltd. (KYKOY) said on Friday it has ended its development and commercialization partnership with Amgen for rocatinlimab, with the Japanese drugmaker... ► Artikel lesen | |
| NOVAVAX | 7,437 | -0,34 % | NOVAVAX INC: Schwäche mit Signalwirkung | ||
| BIOGEN | 149,10 | +1,19 % | Biogen Says FDA Grants Breakthrough Therapy Designation For Litifilimab To Treat CLE | WESTON (dpa-AFX) - Biogen, Inc. (BIIB) announced Wednesday that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for litifilimab (BIIB059) for the treatment... ► Artikel lesen | |
| MAINZ BIOMED | 1,200 | -1,64 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed präsentiert Ergebnisse einer Verifizierungsstudie zu Bauchspeicheldrüsenkrebs auf der AACR-Jahrestagung 2026 | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Konferenz
Mainz Biomed präsentiert Ergebnisse einer Verifizierungsstudie zu Bauchspeicheldrüsenkrebs auf der AACR-Jahrestagung... ► Artikel lesen | |
| VIKING THERAPEUTICS | 24,780 | +1,02 % | Eli Lilly or Viking Therapeutics: Which Stock Is More Likely to be a Millionaire-Maker? | ||
| INTELLIA THERAPEUTICS | 11,105 | +0,14 % | Weekly Buzz: Intellia Gets FDA Nod For ATTRv-PN Trial; Aprea's APR-1051 Paces; CALC Halts KOURAGE | SOUTH SAN FRANCISCO (dpa-AFX) - This week's biotech landscape features key FDA approvals, clinical holds and go-aheads, trial discontinuations, and clinical trial data readouts across key therapeutic... ► Artikel lesen | |
| TEMPUS AI | 51,00 | +0,99 % | Studie von Tempus AI belegt verbesserte Vorhersage für Krebs-Immuntherapie | ||
| BIOCRYST PHARMACEUTICALS | 5,586 | +0,68 % | BioCryst Pharmaceuticals, Inc.: BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema | RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has completed its acquisition of Astria Therapeutics, Inc., initially... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 47,360 | -0,73 % | BioMarin Pharmaceutical Inc.: BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility | SAN RAFAEL, Calif., Jan. 29, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ("BioMarin") announced today that it priced its previously announced... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 17,230 | +0,44 % | SRPT Stock Up 8% on Positive Long-Term Data From Elevidys Study in DMD | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,933 | +1,65 % | PacBio to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026 | ||
| EXELIXIS | 35,060 | +0,49 % | Exelixis-Aktie: Blockbuster-Kandidat Zanzalintinib vor Zulassung | Auf der Suche nach wachstumsstarken Biotech-Unternehmen mit angemessener Bewertung rückt Exelixis ins Blickfeld. Der Onkologiespezialist ist profitabel, verfügt über mehrere in den USA vermarktete Therapien... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 0,800 | -0,74 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million | Toronto, Ontario--(Newsfile Corp. - January 23, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing... ► Artikel lesen | |
| VAXART | 0,370 | 0,00 % | Vaxart, Inc.: Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results | Entered into an exclusive license agreement with Dynavax for the Company's COVID-19 oral pill vaccine candidate for potential cumulative proceeds of up to $700 million plus royalties Completed enrollment... ► Artikel lesen |
Das Unternehmen SAB BIOTHERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -1,35 % bei einem Aktienkurs von 4,370 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SAB BIOTHERAPEUTICS INC finden Sie auf Wallstreet Online.